Macular Degeneration Supplements: What the Clinical Evidence Shows (2026)
Macular degeneration supplements with the strongest clinical evidence are the AREDS2 formula nutrients — lutein (10 mg/day), zeaxanthin (2 mg/day), vitamin C (500 mg/day), vitamin E (400 IU/day), zinc (80 mg/day), and copper (2 mg/day) — which reduced the risk of progressing from intermediate to advanced AMD by approximately 25% in the landmark NIH-funded AREDS2 trial. As a Registered Dietitian Nutritionist, I want to be precise about what this evidence does and does not say: the 25% risk reduction applies to people with documented intermediate AMD, not to everyone with a family history or general eye-health concern. This guide gives you the evidence hierarchy, real dosing numbers, and the honest picture of where the science stops and marketing starts.
Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 60 in developed countries, affecting an estimated 196 million people globally as of 2020, with projections reaching 288 million by 2040 based on Bourne et al., Lancet Global Health (2021). With no pharmaceutical cure for early or intermediate AMD, the AREDS2 supplement formula represents one of the most directly applicable interventions in the clinical evidence base — which is precisely why understanding it correctly matters so much.
TL;DR
- Strongest evidence: AREDS2 formula (lutein 10 mg + zeaxanthin 2 mg + vitamin C 500 mg + vitamin E 400 IU + zinc 80 mg + copper 2 mg) — reduces AMD progression risk by ~25% for intermediate AMD.
- Who benefits: People with intermediate AMD (large drusen) or advanced AMD in one eye — not people with early AMD or healthy eyes.
- Beta-carotene is OUT: AREDS2 replaced it with lutein/zeaxanthin after the CARET trial found beta-carotene increases lung cancer risk in smokers and former smokers.
- Omega-3 null result: AREDS2 tested omega-3 addition — no statistically significant AMD benefit over the base formula.
- Zinc dose controversy: 80 mg/day zinc works but 25 mg/day may be comparably effective with a safer long-term profile.
- Diet before supplements: For healthy eyes, consistent dark-leafy-green intake is more broadly supported than supplementation for AMD prevention.
- Get an eye exam first: Supplementing without a documented AMD stage means supplementing without knowing if you are in the population the evidence addresses.
What Macular Degeneration Is — Staging and Why It Matters
Age-related macular degeneration is a progressive degenerative disease of the macula — the central 5 mm region of the retina responsible for all sharp detail vision including reading, recognizing faces, and driving. AMD is classified in three stages, and this staging is critical because the evidence for supplementation applies only to specific stages.
Early AMD: Characterized by small-to-medium drusen (yellow-white deposits beneath the retinal pigment epithelium) without pigmentary abnormalities or vision loss. Most people with early AMD are unaware of it; it is typically detected on dilated fundus exam or fundus photography. No clinical trial evidence supports AREDS2 supplementation for early AMD — the original AREDS trial showed no statistically significant benefit at this stage.
Intermediate AMD: Defined by at least one large druse (>125 microns) or multiple medium drusen or pigmentary abnormalities in one or both eyes. This is the population in whom AREDS and AREDS2 demonstrated the 25% risk-reduction benefit. People with intermediate AMD may experience minimal visual symptoms but are at substantially elevated risk of progressing to vision-threatening advanced disease. The American Academy of Ophthalmology recommends AREDS2 supplementation for intermediate AMD.
Advanced AMD: Exists in two subtypes — geographic atrophy (GA, also called dry advanced AMD), characterized by loss of retinal pigment epithelium and photoreceptors in the macula creating a crescentic or circular zone of atrophy, and neovascular AMD (also called wet AMD), characterized by abnormal choroidal blood vessel growth (choroidal neovascularization) that causes rapid exudative retinal damage. Both produce significant central vision loss. People with advanced AMD in one eye are in the target population for AREDS2 supplementation to protect the fellow eye.
The biological pathway underlying AMD involves cumulative oxidative damage to the retinal pigment epithelium — the metabolically active cell layer that sustains the photoreceptors — compounded by complement-mediated inflammation, drusen accumulation disrupting RPE-photoreceptor nutrition, and eventual cell death or vascular invasion. This is why antioxidant and anti-inflammatory nutrients form the mechanistic rationale for AMD supplements.
The AREDS and AREDS2 Trials: The Evidence Foundation
No review of macular degeneration supplements is credible without a precise understanding of the AREDS studies — the only large-scale, well-powered, NIH-funded randomized controlled trials in this domain.
AREDS (2001): The original Age-Related Eye Disease Study enrolled 4,757 participants across eleven clinical centers, randomized to antioxidant vitamins alone (vitamin C 500 mg + vitamin E 400 IU + beta-carotene 15 mg), zinc alone (80 mg zinc + 2 mg copper), the combination, or placebo. After an average follow-up of 6.3 years:
- The antioxidant + zinc combination reduced the risk of progressing to advanced AMD by 25% relative to placebo in participants with intermediate AMD or advanced AMD in one eye
- Antioxidants alone reduced risk by 17%; zinc alone by 21%; neither reached the combination’s effect size
- The combination also reduced risk of vision loss ≥3 lines by 19%
Published in Archives of Ophthalmology (2001), this established the first evidence-based supplement formula for AMD.
AREDS2 (2013): Enrolled 4,203 participants with intermediate AMD or advanced AMD in one eye in a 2×2 factorial design. The primary innovation: replacing beta-carotene with lutein (10 mg) + zeaxanthin (2 mg), and testing whether adding omega-3 fatty acids (DHA 350 mg + EPA 650 mg) to the base AREDS formula provided additional benefit.
Key findings from JAMA Ophthalmology (2013):
- Lutein/zeaxanthin substituted for beta-carotene showed comparable AMD protection, with approximately 26% lower risk of advanced AMD in participants with the lowest baseline dietary lutein intake
- Beta-carotene is no longer recommended — particularly for current and former smokers — following the CARET trial’s demonstration of increased lung cancer risk
- Adding omega-3 to the AREDS formula produced no statistically significant additional AMD benefit in the primary analysis
- Reducing zinc from 80 mg to 25 mg showed comparable primary outcomes in the primary analysis, though this is a secondary finding
The AREDS2 formula is now the universal ophthalmological standard for supplement treatment of intermediate AMD.
Lutein and Zeaxanthin: The Core Carotenoid Evidence
Lutein and zeaxanthin are the most evidence-backed individual ingredients in the AMD supplement landscape. These xanthophyll carotenoids concentrate specifically in the macula — forming the yellow macular pigment that provides dual protection: absorbing high-energy blue light before it reaches photoreceptors, and quenching reactive oxygen species generated by the retina’s intense metabolic activity.
Why these two carotenoids specifically concentrate in the eye is not coincidental — specific carotenoid-binding proteins (GSTP1 and StARD3) actively sequester lutein and zeaxanthin in macular tissue from circulating plasma carotenoids. This selectivity means that plasma lutein levels are a crude proxy for macular tissue levels; macular pigment optical density (MPOD), measured via heterochromatic flicker photometry, is the validated biomarker for actual macular carotenoid concentration. A 2019 systematic review by Eisenhauer et al. confirmed that supplemental lutein at ≥6 mg/day consistently increases MPOD, with maximum response at 10 mg/day over 6–12 months of continuous supplementation.
AREDS2 subgroup analysis: The greatest AMD risk-reduction benefit from lutein/zeaxanthin occurred in participants whose baseline dietary carotenoid intake was in the lowest quartile — confirming that supplementation corrects a dietary gap most effectively when the gap is largest. The finding is clinically important: it suggests that people who eat very few dark leafy greens will derive the most benefit from supplementation, while those with high dietary carotenoid intake may see less additional benefit from the supplement.
The beta-carotene replacement rationale: The Carotene and Retinol Efficacy Trial (CARET) found that 30 mg/day beta-carotene + 25,000 IU vitamin A increased lung cancer incidence by 28% and total mortality by 17% in current and former heavy smokers — a finding that stopped the trial early. The Finnish ATBC trial found a 16–18% increase in lung cancer incidence with beta-carotene supplementation in male smokers. AREDS2’s lutein/zeaxanthin substitution showed zero lung cancer signal across all smoking groups. For the 20–30% of AMD patients with a smoking history, lutein/zeaxanthin is a safety-required substitution, not merely a preference.
For an in-depth review of how lutein and zeaxanthin work at the mechanistic level — including MPOD measurement methodology, the third macular carotenoid meso-zeaxanthin, and food-versus-supplement bioavailability comparisons — see our lutein and zeaxanthin for vision guide.
Zinc and Copper: Structural Minerals in the AREDS Formula
Zinc is the most abundant trace mineral in the retina, concentrated in the retinal pigment epithelium where it acts as a cofactor for antioxidant enzymes including superoxide dismutase and catalase. It is also required for converting retinol to retinal for rhodopsin synthesis, linking it to the visual cycle directly. AMD pathology involves RPE dysfunction, and zinc’s dense concentration in this layer provides mechanistic rationale for its inclusion in the AREDS formula.
The 80 mg vs. 25 mg zinc question is one of the genuinely clinically uncertain aspects of the AREDS2 results. The original AREDS used 80 mg elemental zinc per day — 2× the Tolerable Upper Intake Level (UL) of 40 mg/day. AREDS2 tested 25 mg and found no statistically significant difference on the primary AMD endpoint. However, this comparison was a secondary analysis and the trial was not powered to definitively establish non-inferiority of the lower zinc dose for all AMD subgroups.
Long-term 80 mg/day zinc is not without risk: it can impair copper absorption (copper deficiency anemia and neurological symptoms have been reported in patients on high-dose zinc), reduce HDL cholesterol, and interfere with antibiotic absorption. Both formulas include 2 mg copper to offset the zinc-induced copper depletion. Many ophthalmologists now favor 25 mg zinc for long-term supplementation without specific evidence the higher dose adds benefit for their patient’s AMD stage and characteristics.
Copper inclusion is mandatory: Any AREDS-formula supplement taken without accompanying copper supplementation risks progressive copper deficiency over years of high-zinc exposure. Patients assembling their own formulas from separate supplements should verify copper inclusion.
Vitamin C: Aqueous Humor Antioxidant
Vitamin C (ascorbic acid) at 500 mg/day is the third AREDS2 component. The biological rationale is specific to eye anatomy: vitamin C concentrates in the aqueous humor at levels 15–20 times greater than plasma — a physiological priority suggesting active transport and significant oxidative-stress management in this ocular compartment. The retinal pigment epithelium is also a high-ascorbate tissue.
As with all AREDS2 components, the clinical evidence is for the combination formula, not vitamin C in isolation. Independent vitamin C trials for AMD have not replicated an independent benefit signal — suggesting synergistic antioxidant effects with vitamin E and zinc in the full formula. The 500 mg/day dose is well tolerated by virtually all adults; at doses above 2,000 mg/day, oxalate kidney stone risk increases in susceptible individuals, but 500 mg is far below this threshold.
Observational evidence suggests dietary vitamin C is consistently associated with lower cataract rates in population studies, providing a broader eye-health rationale beyond AMD. This is a dietary association rather than RCT evidence for supplementation in cataract prevention.
Vitamin E: Lipid-Membrane Antioxidant
Vitamin E (alpha-tocopherol) at 400 IU/day is the fourth AREDS2 component. Fat-soluble vitamin E concentrates in cell membranes where it interrupts lipid peroxidation chain reactions — mechanistically important in the lipid-rich photoreceptor outer segment membranes, which are dense in polyunsaturated fatty acids and vulnerable to peroxidation from light-induced reactive oxygen species.
Independent vitamin E trials have not shown AMD benefit — the evidence is for the combination formula only. The HOPE trial, the GISSI-Prevenzione trial, and a large meta-analysis by Miller et al. found no cardiovascular or cancer benefits from vitamin E supplementation in isolation, and some analyses suggested increased mortality at doses above 400 IU/day in at-risk populations. The AREDS2 dose of 400 IU should be understood as a guideline, not a starting point for dose escalation. At 400 IU/day, vitamin E has mild antiplatelet activity — patients on warfarin or antiplatelet medications should have INR monitored when adding AREDS2-formula supplementation.
Omega-3 Fatty Acids: The AREDS2 Null Result
Omega-3 fatty acids (DHA and EPA) are biologically important in the retina — DHA constitutes approximately 50–60% of the fatty acid content of photoreceptor outer segment membranes, and EPA is the primary precursor to anti-inflammatory specialized pro-resolving mediators (resolvins and protectins) that modulate immune cell activity in AMD lesions. Despite this biological importance, omega-3 supplementation did not demonstrate additional AMD benefit in AREDS2’s primary analysis.
Several large observational studies — including the BDES (Blue Mountains Eye Study) and the Age-Related Eye Disease Study Research Group’s dietary analyses — found that higher dietary fish consumption was associated with lower AMD risk. These epidemiological associations may reflect dietary patterns that include fish as part of an overall Mediterranean-type diet rather than an isolated omega-3 effect.
Where omega-3 does have evidence: Dry eye disease. The DREAM trial (NEJM, 2018) was a rigorous RCT that found no statistically significant benefit for its primary OSDI outcome at 3,000 mg omega-3 daily vs. olive oil placebo, though earlier meta-analyses were more positive. Omega-3 supplementation at 2,000–3,000 mg/day is a reasonable first-line adjunct for dry eye disease given its excellent safety profile — a different condition from AMD, but one that frequently coexists in the same older adult population. Our dry eye supplements evidence guide reviews the full dry eye evidence, including the DREAM null result context and alternative interventions.
Emerging and Investigational Supplements for AMD
Beyond the AREDS2 formula, several supplements have biological rationale and small-study evidence but lack RCT confirmation in AMD populations. These warrant honest evaluation of what the evidence actually supports.
Saffron (Crocus sativus)
Saffron contains carotenoid derivatives (crocin, crocetin) with antioxidant and neuroprotective properties in animal AMD models. A small Italian RCT by Falsini et al. (2010) enrolled 25 patients with early AMD and found statistically significant improvements in macular function (focal electroretinography response) after 3 months of 20 mg/day saffron supplementation vs. placebo. A follow-up larger Italian RCT published in Invest Ophthalmol Vis Sci (2016) by Piccardi et al. found sustained macular function improvement and improved visual acuity after 14 months.
These are genuinely interesting findings — larger, longer, better-powered trials are needed before saffron can be recommended alongside AREDS2 for AMD. The current evidence is hypothesis-generating and mechanistically plausible, not clinically definitive. Saffron at 20–30 mg/day appears safe in short-term studies.
Bilberry (Vaccinium myrtillus)
Bilberry extract (standardized to anthocyanins) is frequently marketed for vision and AMD. The mechanism involves anthocyanin antioxidant activity and a historically prominent (but now controversial) claim of improved dark adaptation from World War II RAF pilot anecdotes. A rigorous systematic review by Chu et al. (2011) found insufficient RCT evidence to support bilberry supplementation for AMD or other ocular conditions. No well-powered AMD-specific RCT has confirmed benefit. Bilberry is safe, but consumers should understand that marketing claims for AMD prevention significantly outpace the clinical evidence.
Coenzyme Q10 (CoQ10)
CoQ10 is a mitochondrial electron chain component with antioxidant activity in inner mitochondrial membranes. Mitochondrial dysfunction in RPE cells has been implicated in AMD pathogenesis, and CoQ10 levels in blood decline with age. One small RCT (Feher et al., 2005) found that a combination of CoQ10, acetyl-L-carnitine, and omega-3 improved visual acuity and contrast sensitivity in AMD patients over 12 months. This combination trial cannot isolate CoQ10’s contribution, and no large AMD-specific CoQ10 RCT has been conducted. Current evidence is insufficient for a recommendation but CoQ10 is safe at standard supplement doses.
B Vitamins and Homocysteine
Elevated plasma homocysteine is an independent risk factor for AMD — multiple epidemiological studies confirm this association. B vitamins (folate, B6, B12) are essential cofactors in the methylation cycle that metabolizes homocysteine. The Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS) found that daily supplementation with folate (2.5 mg), B6 (50 mg), and B12 (1 mg) reduced AMD incidence by 34% over 7.3 years in women with cardiovascular risk factors. This is suggestive evidence — the trial enrolled a cardiovascular high-risk female population and AMD was a secondary endpoint, limiting generalizability. Given that B12 and folate deficiency are common in older adults (particularly those on metformin or proton pump inhibitors), ensuring B vitamin adequacy through diet or a standard B-complex supplement is a low-risk, biologically coherent approach for older adults concerned about AMD risk, independent of whether it provides a specific AMD benefit.
What the Evidence Does and Does Not Support
The clinical evidence landscape for AMD supplements can be summarized honestly as follows:
Strongly supported (Level I RCT evidence):
- AREDS2 formula for intermediate AMD (both eyes with large drusen) or advanced AMD in one eye
- This is one of the best-evidenced supplement interventions across all health domains — level I evidence from an NIH-funded multi-center RCT
Biologically plausible, supportive observational evidence, no definitive RCT:
- High dietary intake of lutein, zeaxanthin, and omega-3 from food for AMD risk reduction in healthy adults
- B vitamin optimization for homocysteine-AMD risk pathway
- Saffron supplementation (small RCTs; promising but underpowered)
Null RCT results — evidence of no additional benefit over AREDS2:
- Omega-3 supplementation added to the AREDS formula (AREDS2 null result)
- Beta-carotene (replaced by lutein/zeaxanthin; safety signal in smokers)
Insufficient evidence — commonly marketed, not RCT-confirmed for AMD:
- Bilberry, ginkgo biloba, CoQ10 (standalone), turmeric/curcumin, resveratrol
- These lack AMD-specific RCTs with adequate sample sizes and clinical endpoints
Who Should Consider Macular Degeneration Supplement Supplementation
Intermediate AMD (large drusen in one or both eyes): The clearest indication for AREDS2 supplementation. Level I clinical evidence supports this population specifically. If you have received this diagnosis from an ophthalmologist, AREDS2 is a standard recommendation supported by the American Academy of Ophthalmology.
Advanced AMD in one eye: AREDS2 supplementation to protect the fellow eye is also a standard American Academy of Ophthalmology recommendation. Slowing fellow-eye AMD progression is the most impactful application of supplementation in this population, given that advanced AMD has already caused irreversible damage in the affected eye.
Adults 50+ with intermediate AMD family history and low dietary carotenoid intake: The AREDS2 sub-group with the greatest absolute benefit had low baseline dietary lutein intake. For this population, establishing dietary baseline and correcting carotenoid gaps through diet and potentially supplementation is a reasonable approach — though without intermediate AMD diagnosis, the evidence for AREDS2 supplementation specifically is inferential rather than direct.
For a comprehensive overview of which eye vitamins have evidence across multiple conditions beyond AMD — including cataracts, dry eye, and general vision aging — see our best eye vitamins evidence guide.
Who Should Probably Not Start Macular Degeneration Supplementation
People with early AMD or no AMD diagnosis: Neither AREDS nor AREDS2 demonstrated statistically significant benefit for early AMD. The number-needed-to-treat benefit does not emerge until intermediate or advanced AMD. Supplementing without a documented AMD stage means accepting cost and supplement burden without evidence of benefit for your stage.
People expecting supplements to reverse vision loss: No supplement in any RCT has reversed visual acuity already lost to AMD. The evidence is for slowing progression — decelerating rate of deterioration, not restoring damaged photoreceptors. Geographic atrophy and neovascular lesions cause irreversible retinal damage. Supplement expectations must be calibrated to “slowing progression” rather than “recovery.”
Smokers who select a formula containing beta-carotene: Any AMD formula should use lutein/zeaxanthin rather than beta-carotene. Smokers and former smokers who purchase an older-style AREDS formula (not AREDS2) with beta-carotene are trading AMD protection for increased lung cancer risk. Verify the formula version before purchasing.
People with copper deficiency or at risk for copper-zinc imbalance: High-dose zinc without copper supplementation can cause progressive copper depletion. Patients already taking high-dose zinc for other indications who add an 80 mg zinc AREDS formula without coordinating with their physician risk cumulative toxicity.
Vision Supplement Products: What to Verify Against AREDS2 Standards
Commercial vision supplements vary considerably in how closely they match the AREDS2 clinical formula. Many products list AREDS-referenced nutrients at sub-clinical doses, market to AMD patients, and rely on the clinical credibility of the formula name without delivering the evidence-supported doses.
Before purchasing any macular degeneration supplement, verify against these thresholds:
| Ingredient | AREDS2 Clinical Dose | Red Flags |
|---|---|---|
| Lutein | 10 mg/serving | Less than 6 mg; no milligrams stated |
| Zeaxanthin | 2 mg/serving | Absent from formula; no milligrams stated |
| Vitamin C | 500 mg/serving | Less than 250 mg; “antioxidant blend” without stated quantities |
| Vitamin E | 400 IU/serving | Less than 200 IU; unlisted in formulation |
| Zinc (elemental) | 25–80 mg/serving | Any zinc without accompanying copper |
| Copper | 2 mg/serving | Absent when zinc is ≥25 mg |
“AREDS-formula based” or “inspired by AREDS2” without matching these doses is marketing language, not clinical equivalence. Proprietary blends that conceal individual ingredient quantities cannot be evaluated for AREDS2 dose adequacy.
iGenics is one of the more extensively marketed vision supplements with AREDS-aligned clinical positioning — the full ingredient panel, dose verification against AREDS2 standards, and independent review of its formulation are covered in the iGenics review. TheYaVue takes a similar clinical approach with a lutein and zeaxanthin-centered formula; the TheYaVue review examines its ingredient transparency and dose accuracy against published trial standards. Vision 20 uses a different formulation architecture emphasizing zinc synergy with antioxidant carotenoids; the Vision 20 review evaluates whether its zinc and carotenoid dosing meets clinical thresholds. VisiFlora takes an unusual gut-ocular axis approach based on emerging microbiome-retinal research; the VisiFlora review evaluates its probiotic and prebiotic matrix against what the current evidence supports for retinal health.
Diet as the Foundation: Food Sources for AMD Prevention
For adults without diagnosed AMD, consistent dietary lutein and zeaxanthin intake is the most broadly evidenced AMD-risk strategy. Multiple large observational studies — the CAREDS cohort (Moeller et al., 2006), the Blue Mountains Eye Study, and the Rotterdam Eye Study — all found significant inverse associations between dietary carotenoid intake and AMD prevalence.
The practical targets:
| Food | Serving | Lutein + Zeaxanthin |
|---|---|---|
| Kale, cooked | 1 cup | ~23 mg |
| Spinach, cooked | 1 cup | ~20 mg |
| Swiss chard, cooked | 1 cup | ~19 mg |
| Collard greens, cooked | 1 cup | ~14 mg |
| Frozen peas, cooked | 1 cup | ~4 mg |
| Egg yolks | 2 large | ~0.6 mg (highly bioavailable) |
Values approximate. Source: USDA FoodData Central; Hammond et al., Curr Dev Nutr, 2019.
Lutein and zeaxanthin are fat-soluble — consuming cooked greens with olive oil increases carotenoid bioavailability 2–5 times vs. fat-free preparation. Egg yolks provide a modest total dose but in a highly bioavailable lipid matrix estimated at 3–5 times greater per-unit bioavailability than spinach-sourced lutein in some studies.
A Mediterranean dietary pattern — high in dark leafy greens, legumes, fatty fish, olive oil, and colorful produce, with limited processed foods and red meat — is the dietary approach most consistently associated with AMD risk reduction across multiple observational cohort analyses. No RCT has tested a Mediterranean diet versus control diet for AMD endpoints, but the observational evidence has reasonable biological coherence with the mechanistic narrative for oxidative stress and AMD.
Frequently Asked Questions
What supplements have the best evidence for macular degeneration?
The AREDS2 formula — lutein (10 mg), zeaxanthin (2 mg), vitamin C (500 mg), vitamin E (400 IU), zinc (80 mg with 2 mg copper) — has the strongest evidence for intermediate AMD and advanced AMD in one eye, based on the NIH-funded AREDS2 RCT (JAMA Ophthalmology, 2013). No other supplement has been tested with equivalent rigor in an AMD population.
Should I take AREDS2 supplements if I have early AMD?
The clinical trial evidence does not support AREDS2 supplementation for early AMD — AREDS and AREDS2 enrolled people with intermediate AMD or advanced AMD in one eye. For early AMD, the priority is establishing monitoring with fundus photography and OCT and discussing individual risk factors with your ophthalmologist. Supplementation should follow documented staging, not a precautionary response to early disease where trial evidence of benefit is absent.
Does the AREDS2 formula slow geographic atrophy?
AREDS2 demonstrated benefit against overall advanced AMD progression, but subsequent analyses for geographic atrophy (GA) specifically are less consistent. Geographic atrophy represents a distinct pathological process from neovascular AMD, and recent FDA-approved complement pathway inhibitors (pegcetacoplan, avacincaptad pegol) address GA through mechanisms different from AREDS2 antioxidants. AREDS2 remains the standard for intermediate AMD regardless of expected progression pathway.
Why does the AREDS2 formula use lutein instead of beta-carotene?
AREDS2 replaced beta-carotene with lutein/zeaxanthin after the CARET trial found beta-carotene at high doses increased lung cancer incidence by 28% in current and former smokers. Lutein/zeaxanthin showed no lung cancer signal across all smoking groups in AREDS2 while providing comparable AMD protection — and superior protection in people with low baseline dietary carotenoid intake. For more detail on the carotenoid evidence and MPOD, see our lutein and zeaxanthin for vision guide.
Do omega-3 supplements help with macular degeneration?
The AREDS2 trial found no statistically significant additional AMD benefit from omega-3 (DHA + EPA) added to the base AREDS formula. Omega-3 supplementation is better-evidenced for dry eye disease — see the dry eye supplements evidence guide for that evidence. The null AREDS2 AMD result does not negate the biological importance of DHA in photoreceptor membrane composition, but it does mean supplemental omega-3 cannot be recommended as part of the AREDS2 formula for AMD.
Is the zinc dose in AREDS2 (80 mg) safe long-term?
Long-term 80 mg/day zinc exceeds the Tolerable Upper Intake Level (40 mg/day) and can impair copper absorption, reduce HDL, and interfere with immune function. AREDS2 tested 25 mg zinc and found no significant difference in primary AMD outcomes vs. 80 mg, suggesting the lower dose may be sufficient. Many ophthalmologists now prescribe 25 mg zinc formulations for long-term use. Copper supplementation (2 mg/day) is mandatory at any zinc dose ≥25 mg/day to prevent copper depletion. For more on the full AREDS2 nutrient evidence, see our best eye vitamins evidence guide.
What AMD supplements are proven not to work?
Omega-3 addition to AREDS did not improve AMD outcomes in AREDS2. Beta-carotene is replaced by lutein/zeaxanthin due to safety concerns. Bilberry, ginkgo biloba, and CoQ10 lack RCT evidence in AMD populations despite widespread marketing. Antioxidant supplements outside the AREDS2 combination — vitamin E in isolation, vitamin C alone, selenium, magnesium — have not demonstrated AMD benefit in RCTs designed for that endpoint.
The Bottom Line
Macular degeneration supplements have more rigorous clinical evidence supporting them than almost any other supplement category — thanks to the NIH-funded AREDS and AREDS2 trials. That specificity is both the strength and the limitation of the evidence: it applies to intermediate AMD at exact doses that most commercial “eye health” products do not deliver.
If you have intermediate AMD diagnosed by an ophthalmologist, AREDS2 supplementation is one of the strongest evidence-based supplement interventions across all of medicine. A 25% relative risk reduction for progression to vision-threatening advanced AMD is clinically meaningful in a disease with no pharmaceutical alternative for this stage.
If your eyes are healthy or you have early AMD, the supplement evidence does not yet directly apply. The most broadly supported AMD-risk strategy for healthy adults is consistent dietary lutein from dark leafy greens, regular eye exams to establish a baseline fundus photograph, and not smoking.
The practical checklist before purchasing any macular degeneration supplement:
- Do you have an ophthalmologist-confirmed diagnosis of intermediate AMD or advanced AMD in one eye? If not, supplementation is ahead of the evidence.
- Does the product provide at least 6 mg (ideally 10 mg) lutein, 2 mg zeaxanthin, and the remaining AREDS2 components at clinical doses?
- Is copper (2 mg) included to offset zinc-induced depletion?
- Is the product free of beta-carotene if you smoke or have a smoking history?
- Has a third-party testing laboratory verified potency and purity of the specific batch?
Ophthalmologist oversight is the starting point — not optional. Supplementing the AREDS2 formula without a baseline fundus exam to confirm your AMD stage means supplementing without knowing whether you are in the population the evidence addresses.
Our methodology and reviewer credentials are described on the About page. Our product review approach and disclosure practices are detailed on the disclosure page.
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional — including a board-certified ophthalmologist for any eye health concerns — before starting any supplement program, especially if you have a diagnosed eye condition, are pregnant, or take prescription medications.